



Cleveland Clinic Laboratories


Technical Update • June 2022


Cleveland Clinic Laboratories is dedicated to keeping you updated and informed about recent testing changes. This Technical Update is provided on a monthly basis to notify you of any changes to the tests in our catalog.

Recently changed tests are bolded, and they could include revisions to methodology, reference range, days performed, or CPT code. Deleted tests and new tests are listed separately. For your convenience, tests are listed alphabetically and order codes are provided.

To compare the new information with previous test information, refer to the online Test Directory at clevelandcliniclabs. com. Test information is updated in the online Test Directory on the Effective Date stated in the Technical Update. Please update your database as necessary.

For additional detail, contact Client Services at 216.444.5755 or 800.628.6816, or via email at clientservices@ccf.org.





Test Changes

| imm | fective nmediately /2/22 |
|---|--------------------------------|
| & HBA2) Deletion/ | /2/22 |
| | |
| BK Virus Quantitation, Urine For interface clients only–Test build may need to be modified Includes: BK Virus, Urine Interp BK Virus, Urine, IU/mL BK Virus, Urine, Ig II/mL Special Information: Must indicate specimen source. Clinical Information: Detect and quantify BK virus in urine. The quantitative range of this assay is 2.3–8.0 log II/mL (200-100,000,000 II/mL). A negative result (<1.1 log II/mL or <12.2 II/mL) does not rule out the presence of PCR inhibitors in the patient specimen or BK virus DNA concentrations below the level of detection of the assay. Inhibition may also lead to underestimation of viral quantitation. No international standard is currently available for calibration of this assay. Caution should be taken when interpreting results generated by different assay methodologies. If the assay DETECTED the presence of the virus but was not able to accurately quantify the viral concentration, the test result will be reported as "<2.3 log III/mL (<200 IU/mL), not quantifiable." Specimen Requirement: 5 mL random urine in sterile container; Minimum: 1 mL; Refrigerated; Send to Cleveland Clinic Laboratories on the day of collection. Specimen source required. Specimen must be transferred into cobas PCR Urine Sample Kit within 24 hours if neat. If transferred into cobas PCR Urine Sample Kit within 24 hours, stability is increased to 90 days. Refrigerated: 24 hours if neat. If transferred into cobas PCR Urine Sample Kit within 24 hours, stability is increased to 90 days. | /12/22 |

Test Changes (Cont.)

| Test Name | Order Code | Change | Effective Date |
|--|------------|---|--------------------------|
| BK Virus Quantitation, Urine (continued from page 2) | | Methodology: Real-Time Polymerase Chain Reaction (RT-PCR) Reference Range: BK Virus Quantitation, Urine (UBKDNA): Not detected BK Virus IU/mL Urine (UBKCOP): Refer to report BK Virus log IU/mL Urine (UBKLOG): Refer to report Days Performed: Mon-Fri | |
| Blood Parasites | BLDPAR | Specimen Requirement: 2 mL whole blood in EDTA (Lavender) tube; Ambient; Transport to Main campus within 4 hrs. Use STAT courier when necessary. Rapid results can be critical to establishing appropriate therapy | 6/2/22 |
| Cathartic Laxative, Stool | STCATH | Reported: 9 –13 days CPT: 83735; 84100 | effective immediately |
| Chronic Lymphoproliferative Disorder NGS Bone Marrow | LPMNGS | Special Information: The following genes are interrogated: BRAF, MYD88, NOTCH1, SF3B1, STAT3, STAT5B andTP53. Specimen Requirement: 4 mL bone marrow aspirate in EDTA (Lavender) tube; Collection Ambient; Transport Refrigerated Stability: Ambient: If specimen is to be stored longer than 24 hours, it should be placed at 2-8C for up to 7 days. Refrigerated: 7 days Frozen: Unacceptable Days Performed: Mon–Fri CPT: 81445 | effective immediately |
| Chronic Lymphoproliferative Disorder NGS Peripheral Blood | LPPNGS | Special Information: The following genes are interrogated: BRAF, MYD88, NOTCH1, SF3B1, STAT3, STAT5B andTP53. Specimen Requirement: 4 mL peripheral blood in EDTA (Lavender) tube; Collection Ambient; Transport Refrigerated Stability: Ambient: If specimen is to be stored longer than 24 hours, it should be placed at 2–8C for up to 7 days. Refrigerated: 7 days Frozen: Unacceptable Days Performed: Mon–Fri CPT: 81445 | effective immediately |
| Drug Detection Panel, TOF-MS, Umbilical Cord Tissue | DRGTOF | CPT: 80326; 80347; 80364; 80355 | effective immediately |
| Myeloid Panel NGS Bone Marrow | MYNGSM | Special Information: The following genes are interrogated: ABL1, ASXL1, BCOR, BCORL1, BRAF, CALR, CBL, CEBPA, CSF3R, CUX1, DDX41, DNMT3A, EED, ETNK1, ETV6, EZH2, FLT3, GATA1, GATA2, IDH1, IDH2, JAK2, JAK3, KDM6A, KIT, KMT2A, KRAS, LUC7L2, MPL, NF1, NPM1, NRAS, PHF6, PIGA, PPMID, PRPF8, PTEN, PTPN11, RAD2, RIT1, RUNX1, SETBP1, SF3B1, SH2B3, SMC1A, SMC3, SRSF2, STAG2, STAT3, STAT5B, SUZ12, TET2, TP53, U2AF1, WT1, and ZRSR2. Clinical Limitation: This test does not evaluate for fusions. For a combined evaluation including fusions relevant to acute leukemias, the Acute Leukemia NGS panel is recommended. Clinical Information: Molecular evaluation of known or suspected chronic myeloid neoplasms, including but not limited to myeloproliferative neoplasms, myelodysplastic syndromes, and overlap myelodysplastic/myeloproliferative neoplasms. Evaluates for single nucleotide variants, small insertions and deletions within the covered regions of the targeted genes. Specimen Requirement: 4 mL bone marrow aspirate in EDTA (Lavender) tube; Collection Ambient; Transport Refrigerated Stability: Ambient: If specimen is to be stored longer than 24 hours, it should be placed at 2-8 C for up to 7 days. Refrigerated: 7 days Frozen: Unacceptable CPT: 81455 | effective immediately |

Test Changes (Cont.)

| Test Name | Order Code | Change | Effective Date |
|---------------------------------------|------------|---|--------------------------|
| Myeloid Panel NGS Peripheral Blood | MYNGSP | Special Information: The following genes are interrogated: ABL1, ASXL1, BCOR, BCORL1, BRAF, CALR, CBL, CEBPA, CSF3R, CUX1, DDX41, DNMT3A, EED, ETNK1, ETV6, EZH2, FLT3, GATA1, GATA2, IDH1, IDH2, JAK2, JAK3, KDM6A, KIT, KMT2A, KRAS, LUC7L2, MPL, NF1, NPM1, NRAS, PHF6, PIGA, PPMID, PRPF8, PTEN, PTPN11, RAD2, RIT1, RUNX1, SETBP1, SF3B1, SH2B3, SMC1A, SMC3, SRSF2, STAG2, STAT3, STAT5B, SUZ12, TET2, TP53, U2AF1, WT1, and ZRSR2. | effective immediately |
| | | Clinical Limitation: This test does not evaluate for fusions. For a combined evaluation including fusions relevant to acute leukemias, the Acute Leukemia NGS panel is recommended. | |
| | | Clinical Information: Molecular evaluation of known or suspected chronic myeloid neoplasms, including but not limited to myeloproliferative neoplasms, myelodysplastic syndromes, and overlap myelodysplastic/myeloproliferative neoplasms. Evaluates for single nucleotide variants, small insertions and deletions within the covered regions of the targeted genes. | |
| | | Specimen Requirement: 4 mL peripheral blood in EDTA (Lavender) tube; Collection Ambient; Transport Refrigerated | |
| | | Stability: Ambient: If specimen is to be stored longer than 24 hours, it should be placed at 2-8 C for up to 7 days. Refrigerated: 7 days Frozen: Unacceptable CPT: 81455 | |
| Routine Flu A/B & RSV | RTFRSV | Stability: Ambient: 24 hrs Refrigerated: 96 hours Frozen: Unacceptable | effective immediately |

New Tests

| Test Name | Order Code | Change | Effective Date |
|--|------------|---|--------------------------|
| Acute Leukemia NGS Panel, Blood | HDPNGS | Special Information: RNA genes: ABL1, ABL2, AFDN, ALK, BCL11B, BCL2, BCL3, BCL6, BCR, BIRC3, BLNK, CBFB, CBL, CCND1, CCND2, CCND3, CD274, CD28, CDK6, CDKN2A, CEBPA, CEBPD, CEBPE, CEBPG, CHD1, CHIC2, CIITA, CREBBP, CRLF2, CSF1R, CTLA4, DEK, DGKH, DUSP22, EBF1, EIF4A1, EPOR, ERG, ETV6, FGFR1, FLT3, FOXP1, GLIS2, HLF, ID4, IKZF1, IKZF2, IKZF3, IL2RB, IRF4, IRF8, ITK, JAK2, KAT6A, KLF2, LMO1, LMO2, LYN, MALT1, MECOM, KMT2A, MEF2D, MKL1, MLF1, MLLT10, MUC1, MYC, MYH11, NF1, NFKB2, NOTCH1, NTRK3, NUP214, NUP98, NUTM1, P2RY8, PAG1, PAX5, PBX1, PDCD1, PDCD1LG2, PDGFRA, PDGFRB, PICALM, PML, PRDM16, PTK2B, RARA, RBM15, ROS1, RUNX1, RUNX1T1, SEMA6A, SETD2, STIL, SYK, TAL1, TCF3, TFG, TLX1, TLX3, TP63, TSLP, TYK2, VAV1, ZCCHC7, ZNF384. DNA genes: ABL1, ASXL1, BCOR, BCORL1, BRAF, CALR, CBL, CDKN2A, CEBPA, CSF3R, CUX1, DDX41, DNMT3A, EED, ETNK1, ETV6, EZH2, FBXW7, FLT3, GATA1, GATA2, GNAS, IDH1, IDH2, IKZF1, JAK2, JAK3, KDM6A, KIT, KMT2A, KRAS, LUC7L2, MPL, MYDB8, NF1, NOTCH1, NPM1, NRAS, PAX5, PHF6, PIGA, PPM1D, PRPF8, PTEN, PTPN11, RAD21, RIT1, RUNX1, SETBP1, SF3B1, SH2B3, SMC1A, SMC3, SRSF2, STAG2, STAT3, STAT5B, SUZ12, TET2, TP53, UZAF1, WT1, ZRSR2. Clinical Limitation: Not to be ordered concurrently with the Hematologic Neoplasm Fusion NGS Panel or the Chronic Myeloid NGS Panel, since this panel includes all targeted regions from those panels. Clinical Information: DNA and RNA combination testing to evaluate for single nucleotide variants, small insertions and deletions, and common fusions in acute hematologic malignancies (acute myeloid and acute lymphoblastic leukemias); content includes all of the fusion targets of Hematologic Neoplasm Fusion NGS Panel as well as all of the DNA targets in the Chronic Myeloid NGS Panel. Specimen Requirement: 8 mL peripheral blood in EDTA (Lavender) tube; Collection Ambient; Transport Refrigerated; Refrigerate ASAP Stability: Ambient: If specimen is to be stored longer than 24 hours, it should be placed at 2-8 C for up to 3 days. If testing is delayed, pending specimen triaging, | effective immediately |
| Acute Leukemia NGS Panel, Bone Marrow | HDMNGS | Special Information: RNA_genes: ABL1, ABL2, AFDN, ALK, BCL11B, BCL2, BCL3, BCL6, BCR, BIRC3, BLNK, CBFB, CBL, CCND1, CCND2, CCND3, CD274, CD28, CDK6, CDKN2A, CEBPA, CEBPD, CEBPE, CEBPG, CHD1, CHIC2, CIITA, CREBBP, CRLF2, CSF1R, CTLA4, DEK, DGKH, DUSP22, EBF1, EIF4A1, EPOR, ERG, ETV6, FGFR1, FLT3, FOXP1, GLIS2, HLF, ID4, IKZF1, IKZF2, IKZF3, IL2RB, IRF4, IRF8, ITK, JAK2, KAT6A, KLF2, LMO1, LMO2, LYN, MALT1, MECOM, KMT2A, MEF2D, MKL1, MLF1, MLLT10, MUC1, MYC, MYH11, NF1, NFKB2, NOTCH1, NTRK3, NUP214, NUP98, NUTM1, P2RY8, PAG1, PAX5, PBX1, PDCD1, PDCD1LG2, PDGFRA, PDGFRB, PICALM, PML, PRDM16, PTK2B, RARA, RBM15, ROS1, RUNX1, RUNX1T1, SEMA6A, SETD2, STIL, SYK, TAL1, TCF3, TFG, TLX1, TLX3, TP63, TSLP, TYK2, VAV1, ZCCHC7, ZNF384. DNA_genes: ABL1, ASXL1, BCOR, BCORL1, BRAF, CALR, CBL, CDKN2A, CEBPA, CSF3R, CUX1, DDX41, DNMT3A, EED, ETNK1, ETV6, EZH2, FBXW7, FLT3, GATA1, GATA2, GNAS, IDH1, IDH2, IKZF1, JAK2, JAK3, KDM6A, KIT, KMT2A, KRAS, LUC7L2, MPL, MYD88, NF1, NOTCH1, NPM1, NRAS, PAX5, PHF6, PIGA, PPM1D, PRPF8, PTEN, PTPN11, RAD21, RIT1, RUNX1, SETBP1, SF3B1, SH2B3, SMC1A, SMC3, SRSF2, STAG2, STAT3, STAT5B, SUZ12, TET2, TP53, U2AF1, WT1, ZRSR2. Clinical Limitation: Not to be ordered concurrently with the Hematologic Neoplasm Fusion NGS Panel or the Chronic Myeloid NGS Panel, since this panel includes all targeted regions from those panels. (continued on page 6) | effective immediately |

| Test Name | Order Code | Change | Effective Date |
|--|------------|--|--------------------------|
| Acute Leukemia NGS Panel, Bone Marrow (continued from page 5) | | Clinical Information: DNA and RNA combination testing to evaluate for single nucleotide variants, small insertions and deletions, and common fusions in acute hematologic malignancies (acute myeloid and acute lymphoblastic leukemias); content includes all of the fusion targets of Hematologic Neoplasm Fusion NGS Panel as well as all of the DNA targets in the Chronic Myeloid NGS Panel. | |
| | | Specimen Requirement: 8 mL bone marrow aspirate in EDTA (Lavender) tube; Collection Ambient; Transport Refrigerated; Refrigerate ASAP | |
| | | Stability: Ambient: If specimen is to be stored longer than 24 hours, it should be placed at 2-8 C for up to 3 days. If testing is delayed, awaiting specimen triaging, store as NUCBUF Refrigerated: Stored up to 3 days. If testing is delayed, awaiting specimen triaging, store as NUCBUF | |
| | | Frozen: Unacceptable | |
| | | Methodology: Next Gen Sequencing | |
| | | Days Performed: Mon–Fri | |
| | | Reported: 10 days CPT: 81455 | |
| Acute Leukemia NGS Panel, Other | HDONGS | Special Information: RNA_genes: ABL1, ABL2, AFDN, ALK, BCL11B, BCL2, BCL3, BCL6, BCR, BIRC3, BLNK, CBFB, CBL, CCND1, CCND2, CCND3, CD274, CD28, CDK6, CDKN2A, CEBPA, CEBPD, CEBPE, CEBPG, CHD1, CHIC2, CIITA, CREBBP, CRLF2, CSF1R, CTLA4, DEK, DGKH, DUSP22, EBF1, EIF4A1, EPOR, ERG, ETV6, | effective immediately |
| | | FGFR1, FLT3, FOXP1, GLIS2, HLF, ID4, IKZF1, IKZF2, IKZF3, IL2RB, IRF4, IRF8, ITK, JAK2, KAT6A, KLF2, LM01, LM02, LYN, MALT1, MECOM, KMT2A, MEF2D, MKL1, MLF1, MLLT10, , MUC1, MYC, MYH11, NF1, NFKB2, NOTCH1, NTRK3, NUP214, NUP98, NUTM1, P2RY8, PAG1, PAX5, PBX1, PDCD1, PDCD1LG2, PDGFRA, PDGFRB, PICALM, PML, PRDM16, PTK2B, RARA, RBM15, ROS1, RUNX1, RUNX1T1, SEMA6A, SETD2, STIL, SYK, TAL1, TCF3, TFG, TLX1, TLX3, TP63, TSLP, TYK2, VAV1, ZCCHC7, ZNF384. | |
| | | DNA_genes: ABL1, ASXL1, BCOR, BCORL1, BRAF, CALR, CBL, CDKN2A, CEBPA, CSF3R, CUX1, DDX41, DNMT3A, EED, ETNK1, ETV6, EZH2, FBXW7, FLT3, GATA1, GATA2, GNAS, IDH1, IDH2, IKZF1, JAK2, JAK3, KDM6A, KIT, KMT2A, KRAS, LUC7L2, MPL, MYD88, NF1, NOTCH1, NPM1, NRAS, PAX5, PHF6, PIGA, PPM1D, PRPF8, PTEN, PTPN11, RAD21, RIT1, RUNX1, SETBP1, SF3B1, SH2B3, SMC1A, SMC3, SRSF2, STAG2, STAT3, STAT5B, SUZ12, TET2, TP53, U2AF1, WT1, ZRSR2. | |
| | | Clinical Limitation: Testing of peripheral blood or fresh/buffy coat bone marrow aspirate is preferred to this test on FFPE when those samples are available and representative of disease state. | |
| | | Not to be ordered concurrently with the Hematologic Neoplasm Fusion NGS Panel or the Chronic Myeloid NGS Panel, since this panel includes all targeted regions from those panels. | |
| | | Clinical Information: DNA and RNA combination testing to evaluate for single nucleotide variants, small insertions and deletions, and common fusions in acute hematologic malignancies (acute myeloid and acute lymphoblastic leukemias); content includes all of the fusion targets of Hematologic Neoplasm Fusion NGS Panel as well as all of the DNA targets in the Chronic Myeloid NGS Panel. | |
| | | Specimen Requirement: Twenty unstained and unbaked slides; Ambient; Need 20 charged, unbaked, unstained slides or 10 x 7 micron curls (scrolls) plus 1 H&E slide with best tumor area circled containing at least 8% tumor | |
| | | Stability: Ambient: FFPE tissue and clot section slides and curls are transported and stored at ambient temperature or refrigerated indefinitely Refrigerated: FFPE tissue and clot section slides and curls are transported and stored at ambient temperature or refrigerated indefinitely Frozen: Unacceptable | |
| | | Methodology: Next Gen Sequencing | |
| | | Days Performed: Mon-Fri | |
| | | | |
| | | Reported: 10 days CPT: 81455 | |

New Tests (Cont.)

| Test Name | Order Code | Change | Effective Date |
|---|------------|---|--------------------------|
| Chronic Lymphoproliferative Disorder NGS Other | LPONGS | Special Information: The following genes are interrogated: BRAF, MYD88, NOTCH1, SF3B1, STAT3, STAT5B and TP53. Specimen Requirement: Ten unstained and unbaked slides; Ambient; Need 10 charged, unbaked, unstained slides or 10 x 7 micron curls (scrolls) plus 1 H&E with best tumor area circled containing at least 10% tumor. Stability: Ambient: Clot section slides and curls are transported and stored at ambient temperature or refrigerated indefinitely. Refrigerated: Clot section slides and curls are transported and stored at ambient temperature or refrigerated indefinitely. Frozen: Unacceptable Methodology: Next Generation DNA Sequencing Days Performed: Mon–Fri Reported: Mon–Fri CPT: 81445 | effective immediately |
| Hematologic Neoplasm Fusion NGS Panel, Blood | HFPNGS | Special Information: ABL1, ABL2, ALK, BCL11B, BCL2, BCL3, BCL6, BCR, BIRC3, BLNK, CBFB, CBL, CCND1, CCND2, CCND3, CD274, CD28, CDK6, CDKN2A, CEBPA, CEBPD, CEBPE, CEBPG, CHD1, CHIC2, CIITA, CREBBP, CRLF2, CSF1R, CTLA4, DEK, DGKH, DUSP22, EBF1, EIF4A1, EPOR, ERG, ETV6, FGFR1, FLT3, FOXP1, GLIS2, HLF, ID4, IKZF1, IKZF2, IKZF3, IL2RB, IRF4, IRF8, ITK, JAK2, KAT6A, KLF2, LMO1, LMO2, LYN, MALT1, MECOM, KMT2A, MEF2D, MKL1, MLF1, MLLT10, MLLT4, MUC1, MYC, MYH11, NF1, NFKB2, NOTCH1, NTRK3, NUP214, NUP98, NUTM1, P2RY8, PAG1, PAX5, PBX1, PDCD1, PDCD1LG2, PDGFRA, PDGFRB, PICALM, PML, PRDM16, PTK2B, RARA, RBM15, ROS1, RUNX1, RUNX1T1, SEMA6A, SETD2, STIL, SYK, TAL1, TCF3, TFG, TLX1, TLX3, TP63, TSLP, TYK2, VAV1, ZCCHC7, ZNF384 Clinical Information: Detects common fusions in hematologic malignancies. Content is identical to the fusion component genes in the Acute Leukemia NGS panel. Specimen Requirement: 4 mL peripheral blood in EDTA (Lavender) tube; Collection Ambient; Transport Refrigerated Stability: Ambient: If specimen is to be stored longer than 24 hours, it should be placed at 2-8 C for up to 3 days. If testing is to be delayed, pending triage, store as NUCBUF Refrigerated: Stored up to 3 days. If testing is to be delayed, pending triage, store as NUCBUF Frozen: Unacceptable Methodology: Next Gen Sequencing Days Performed: Mon-Fri Reported: 10 days CPT: 81455 | effective immediately |
| Hematologic Neoplasm Fusion NGS Panel, Bone Marrow | HFMNGS | Special Information: ABL1, ABL2, AFDN, ALK, BCL11B, BCL2, BCL3, BCL6, BCR, BIRC3, BLNK, CBFB, CBL, CCND1, CCND2, CCND3, CD274, CD28, CDK6, CDKN2A, CEBPA, CEBPD, CEBPE, CEBPG, CHD1, CHIC2, CIITA, CREBBP, CRLF2, CSF1R, CTLA4, DEK, DGKH, DUSP22, EBF1, EIF4A1, EPOR, ERG, ETV6, FGFR1, FLT3, FOXP1, GLIS2, HLF, ID4, IKZF1, IKZF2, IKZF3, IL2RB, IRF4, IRF8, ITK, JAK2, KAT6A, KLF2, KMT2A, LMO1, LMO2, LYN, MALT1, MECOM, MEF2D, MKL1, MLF1, MLLT10, MUC1, MYC, MYH11, NF1, NFKB2, NOTCH1, NTRK3, NUP214, NUP98, NUTM1, P2RY8, PAG1, PAX5, PBX1, PDCD1, PDCD1LG2, PDGFRA, PDGFRB, PICALM, PML, PRDM16, PTK2B, RARA, RBM15, ROS1, RUNX1, RUNX1T1, SEMA6A, SETD2, STIL, SYK, TAL1, TCF3, TFG, TLX1, TLX3, TP63, TSLP, TYK2, VAV1, ZCCHC7, ZNF384. Clinical Information: Detects common fusions in hematologic malignancies. Content is identical to the fusion component genes in the Acute Leukemia NGS panel. Specimen Requirement: 4 mL bone marrow aspirate in EDTA (Lavender) tube; Collection Ambient; Transport Refrigerated; Refrigerate ASAP Stability: Ambient: If specimen is to be stored longer than 24 hours, it should be placed at 2-8 C for up to 3 days. If testing is to be delayed, pending triage, store as NUCBUF Refrigerated: Stored up to 3 days. If testing is to be delayed, pending triage, store as NUCBUF Frozen: Unacceptable (continued on page 8) | effective immediately |

New Tests (Cont.)

| Test Name | Order Code | Change | Effective Date |
|---|------------|--|--------------------------|
| Hematologic Neoplasm Fusion NGS Panel, Bone Marrow (continued from page 7) | | Methodology: Next Gen Sequencing Days Performed: Mon–Fri Reported: 10 days CPT: 81455 | |
| Hematologic Neoplasm Fusion NGS Panel, Other | HFONGS | Special Information: ABL1, ABL2, AFDN, ALK, BCL11B, BCL2, BCL3, BCL6, BCR, BIRC3, BLNK, CBFB, CBL, CCND1, CCND2, CCND3, CD274, CD28, CDK6, CDKN2A, CEBPA, CEBPD, CEBPE, CEBPG, CHD1, CHIC2, CIITA, CREBBP, CRLF2, CSF1R, CTLA4, DEK, DGKH, DUSP22, EBF1, EIF4A1, EPOR, ERG, ETV6, FGFR1, FLT3, FOXP1, GLIS2, HLF, ID4, IKZF1, IKZF2, IKZF3, IL2RB, IRF4, IRF8, ITK, JAK2, KAT6A, KLF2, KMT2A, LMO1, LMO2, LYN, MALT1, MECOM, MEF2D, MKL1, MLF1, MLLT10, MUC1, MYC, MYH11, NF1, NFKB2, NOTCH1, NTRK3, NUP214, NUP98, NUTM1, P2RY8, PAG1, PAX5, PBX1, PDCD1, PDCD1LG2, PDGFRA, PDGFRB, PICALM, PML, PRDM16, PTK2B, RARA, RBM15, ROS1, RUNX1, RUNX1T1, SEMA6A, SETD2, STIL, SYK, TAL1, TCF3, TFG, TLX1, TLX3, TP63, TSLP, TYK2, VAV1, ZCCHC7, ZNF384. Clinical Information: Detects common fusions in hematologic malignancies. Content is identical to the fusion component genes in the Acute Leukemia NGS panel. Specimen Requirement: Ten unstained and unbaked slides; Collection Ambient; | effective immediately |
| | | Transport Ambient; Need 10 charged, unbaked, unstained slides or 10 x 7 micron curls (scrolls) plus 1 H&E slide with best tumor area circled containing at least 8% tumor Stability: Ambient: FFPE tissue and clot section slides and curls are transported and stored at ambient temperature or refrigerated indefinitely Refrigerated: FFPE tissue and clot section slides and curls are transported and stored at ambient temperature or refrigerated indefinitely Frozen: Unacceptable Methodology: Next Gen Sequencing | |
| | | Days Performed: Mon–Fri Reported: 10 days | |
| Myeloid NGS Panel Other | MYNGSO | CPT: 81455 Special Information: The following genes are interrogated: ABL1, ASXL1, BCOR, BCORL1, BRAF, CALR, CBL, CEBPA, CSF3R, CUX1, DDX41, DNMT3A, EED, ETNK1, ETV6, EZH2, FLT3, GATA1, GATA2, IDH1, IDH2, JAK2, JAK3, KDM6A, KIT, KMT2A, KRAS, LUC7L2, MPL, NF1, NPM1, NRAS, PHF6, PIGA, PPMID, PRPF8, PTEN, PTPN11, RAD2, RIT1, RUNX1, SETBP1, SF3B1, SH2B3, SMC1A, SMC3, SRSF2, STAG2, STAT3, STAT5B, SUZ12, TET2, TP53, U2AF1, WT1, and ZRSR2. Clinical Limitation: This test does not evaluate for fusions. For a combined evaluation including fusions relevant to acute leukemias, the Acute Leukemia NGS | effective immediately |
| | | panel is recommended. Clinical Information: Molecular evaluation of known or suspected chronic myeloid neoplasms, including but not limited to myeloproliferative neoplasms, myelodysplastic syndromes, and overlap myelodysplastic/myeloproliferative neoplasms. Evaluates for single nucleotide variants, small insertions and deletions within the covered regions of the targeted genes. | |
| | | Specimen Requirement: Ten unstained and unbaked slides; Ambient; Need 10 charged, unbaked, unstained slides or 10 x 7 micron curls (scrolls) plus 1 H&E with best tumor area circled containing at least 10% tumor. | |
| | | Stability: Ambient: Clot section slides and curls are transported and stored at ambient temperature or refrigerated indefinitely. Refrigerated: Clot section slides and curls are transported and stored at ambient temperature or refrigerated indefinitely. Frozen: Unacceptable | |
| | | Methodology: Next Generation DNA Sequencing | |
| | | Days Performed: Mon–Fri | |
| | | Reported: 10 days CPT: 81455 | |

Discontinued Tests

| Test Name | Order Code | Test Information | Effective Date |
|--|------------|---|--------------------------|
| ALL Panel NGS Bone Marrow | ALLBM | Test will no longer be orderable. | effective immediately |
| ALL Panel NGS Peripheral Blood | ALLPB | Test will no longer be orderable. | effective immediately |
| Giardia lamblia IgG, IgA, IgM | GIAGAM | Test will no longer be orderable. Recommended replacement test is Cryptosporidium & Giardia Antigens by EIA (OVAPSC). | effective immediately |
| Hematologic Neoplasm Next Generation Sequencing Panel Marrow | HNMNGS | Test will no longer be orderable. For lab use only. | effective immediately |
| Hematologic Neoplasm Next Generation Sequencing Panel Peripheral Blood | HNPNGS | Test will no longer be orderable. For lab use only. | effective immediately |
| Legionella IgM Abs | LEGMAB | Test will no longer be orderable. Recommended replacement tests are Legionella Culture (LEGCUL), Legionella Urinary Ag (LEGUAG) or Legionella pneumophila PCR (LEGPCR). | effective immediately |
| Legionella pneumophila Antibody (Types 1-6), IgG by IFA | SLEGAB | Test will no longer be orderable. Recommended replacement tests are Legionella Culture (LEGCUL), Legionella Urinary Ag (LEGUAG) or Legionella pneumophila PCR (LEGPCR). | effective immediately |